DAFNA Capital Management »

Vyne Therapeutics shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of Vyne Therapeutics (VYNE) shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in Vyne Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Vyne Therapeutics held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Vyne Therapeutics by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2025-06-30 $1.0M 636k 1.65
2025-03-31 $1.0M 636k 1.58

More positions owned by DAFNA Capital Management

Stereotaxis Com New (STXS)
Spdr S&p Biotech Etf Etf (XBI)
Revolution Medicines (RVMD)
Cytokinetics Com New (CYTK)
AtriCure (ATRC)
Merus N V (MRUS)
Ishares Nasdaq Biotech Indx Etf (IBB)
Ideaya Biosciences (IDYA)
Axogen (AXGN)
Xenon Pharmaceuticals (XENE)
Neurocrine Biosciences (NBIX)
Arcus Biosciences Incorporated (RCUS)
Syndax Pharmaceuticals (SNDX)
Day One Biopharmaceuticals I (DAWN)
Ascendis Pharma A/s Sponsored Adr (ASND)

View all positions for DAFNA Capital Management

Top funds holding Vyne Therapeutics

Baker Bros. Advisors
Acorn Capital Advisors
Shay Capital
Acadian Asset Management
Ikarian Capital
Two Sigma Investments
Vanguard Group
Jane Street
Geode Capital Management
Boothbay Fund Management
Bridgeway Capital Management
Susquehanna International
Two Sigma Advisers
Rangeley Capital
Corsair Capital Management

View all funds holding Vyne Therapeutics